drugset / Trial / NCT07266545

RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)

NCT07266545

Phase 4 Recruiting 120 enrolled Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research is to understand how changes in RNA editing relate to treatment response in unipolar and bipolar depression.

Timeline

Start
2026-02-17
Primary completion
2028-12-31
Completion
2030-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cariprazine Small molecule 3 mg Oral
Subject Vortioxetine Unknown 20 mg